This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing Regenxbio's Functional Data from Phase I/II Affinity Duchenne Trial of RGX-202
Ticker(s): RGNXWho's the expert?
Institution: BLINDED
- Assistant Professor of Pediatric Neurology at Baylor College of Medicine.
- Manages 36 patients with SMA and 85 patients with DMD per year.
- PI on several clinical trials including the pamrevlumab study; Clinical and research interest in muscular dystrophy with focus on Duchenne Muscular Dystrophy.
Interview GoalThis conversation will focus on the treatment landscape and potential use of RGX-202 gene therapy for patients with Duchenne muscular dystrophy.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
